Indication intelligence, analysis and sector perception

RegMed’s close: retreating, reversing and reverting to maintain gains

November 4, 2015 5:31pm

The sector was oversold and now is possibly overbought in the short term and it’s looking for a reason to pause and we’re seeing some of it today

Keeping you posted on the daily activity in “our” universe! Subscription required, read more … http://www.regmedinvestors.com/user/register

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

U.S. stocks, unable to follow a rally in European and Asian stocks on Wednesday closed lower Wednesday, after a solid start to November after Federal Reserve Chair Janet Yellen said the U.S. economy is "performing well" and could justify an interest rate hike in December.

The NASDAQ closed DOWN -2.65 or -0.05% to 5,142.48 and the DOW closed DOWN -50.57 or -0.28% to 17,867.58.

Henry’omics:

The stem, cell and gene therapy RegMed sector flipped and slipped turning neutral at the mid-day trying to hold onto the past two (2) days of “ups” while traders cherry-picked strength to be sold into.

The iShares Nasdaq Biotechnology ETF (IBB) pared losses to trade mildly lower <.43% > on Wednesday following Tuesday’s +0.30% following Monday’s advance of +3.87% when it had closed Friday DOWN -3.09 or -0.94%.

My interpretation of the fear index, the CBOE Volatility Index (VIX) closed on Wednesday above 15, an increase from Tuesday’s near 14 following Monday’s below 14.

Earnings:

Most would agree the fundamental situation has not changed much, with exception of a handful of “so-so” received financial results/earnings reports, which is different than the previous quarter:

Bluebird bio (BLUE) reported <11/4> a Q3/15 net loss of -$42.9 m or -$1.18 per share with $901.7 M in cash, BLUE closed down -$3.49 to $90.15;

Fate Therapeutics (FATE) reported <11/4> a Q3/15 net loss of -$6.8 M or -$0.24 per share with $72.9 m in cash and is up <today> post the conference call +$0.25 to $4.77;

MiMedx (MDXG) reported <10/29> a Q3/15 net income of +$6.6 M or +$0.06 per share with $41.1 M in cash and is up <today> +$0.16 to $7.55;

Sangamo Biosciences (SGMO) reported <10/28> a Q3/15 net loss of -$9.2 M or -$0.13 per share with $219.7 M in cash and is down <today> -$0.12 to $7.78;

Spark Therapeutics (ONCE) reported <11/4> a Q3/15 net loss of -$16.9 M or -$0.70 per share with $212.2 M in cash and is up <today> +$2.77 to $60.03;

StemCells (STEM) reported <11/2> a net loss of -$9.64 m or -$0.09 per share with $21.1 m in cash and is up +$0.02 to $0.42.

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

The SCGT & RM equities opened negative with an Advance/Decline line (A/DL) of 19/21 and 3 flats;.

The first hour (10:30 am) flipped to the positive with an A/DL of 25/17 and 1 flat;

The second hour (11:30 am) fell to a negative A/DL of 19/22 and 3 flats;

The mid-day concluded neutral with an A/DL of 20/20 and 3 flats;

The 2 pm A/DL flipped back to a positive A/DL at 26/12 and 3 flats;

The 3 pm A/DL maintained a positive A/DL of 30/11 and 2 flats;

The closing bell rang positive to end the session with an A/DL of 28/12 and 3 flats.

Price gain/price loss, Wednesday’s review of Tuesday’s follow-up on Monday’s eighteen (18) up stocks - $’s up as compared to Friday’s close:

bluebird bio (BLUE) – closed down on Wednesday -$3.49 following Tuesday’s +$9.26 after Monday’s+$7.25 having closed down <Friday> -$1.96 ;

Cellectis ADR (CLLS) – closed down on Wednesday -$3.57 following Tuesday’s +$7.24 after Monday’s +$4.89 having closed up <Friday> +$0.36;

Kite Pharma (KITE) closed down on Wednesday -$0.47 following Tuesday’s +$0.32 after Monday’s +$4.28 having closed down <Friday> -$0.72;

Spark Therapeutics (ONCE) closed up on Wednesday +$2.77 following Tuesday’s decline of -$0.82 after Monday’s +$4.18 having closed down <Friday> -$1.21;

Bellicum (BLCM) closed up on Wednesday +$0.14 following Tuesday‘s +$0.24 after Monday’s +$2.33 having closed down <Friday> -$0.50;

Intrexon (XON) closed up on Wednesday +$0.94 on Wednesday following Tuesday’s +$3.90 after Monday’s +$1.92 having closed down <Friday> -$0.13;

Juno Therapeutics (JUNO) closed down on Wednesday -$0.07 following Tuesday’s +$2.14 after Monday’s +$1.90 having closed up <Friday> +$0.37;

uniQure (QURE) closed up on Wednesday +$1.56 following Tuesday’s +$0.25 after Monday’s +$1.05 having closed down <Friday> -$0.13;

Osiris (OSIR) closed up on Wednesday +$0.56 following Tuesday’s -$0.30 after Monday’s +$1.05 having closed up <Friday> +$0.60;

Applied Genetic Technologies (AGTC) closed up on Wednesday +$0.71 following Tuesday’s +$0.05 after Monday’s +$1.03 having closed down <Friday> -$0.08;

Regenxbio (RGNX) up on Wednesday +$0.90 following Tuesday’s +$0.69 after Monday’s +$0.98 having closed down <Friday> -$0.13;

Sangamo (SGMO) closed down on Wednesday -$0.12 following Tuesday’s +$0.02 on after Monday’s +$0.83 having closed down <Friday> +$0.64;

Aduro Biotech (ADRO) closed up on Wednesday +$0.46 following Tuesday’s +$0.08 after Monday’s +$0.74 having closed up <Friday> +$0.11;

Avalanche (AAVL) closed up on Wednesday +$0.12 following Tuesday’s +$0.23 after Monday’s +$0.62 having closed down <Friday> +$0.03;

MiMedx (MDXG) closed up on Wednesday +$0.16 following Tuesday’s -$0.42 after Monday’s +$0.53 having closed down <Friday> -$0.01;

Asterias Therapeutics (NYSEMKT: AST) closed up on Wednesday +$0.43 following Tuesday’s -$0.07 after Monday’s +$0.50 having closed down <Friday> +$0.33;

Fibrocell FCSC) closed up on Wednesday +$0.12 following Tuesday’s +$0.16 after Monday’s +$0.46 having closed down <Friday> -$0.28;

Dosing the sector – what a day for the 43 Patients:

Open: NEGATIVE with 21 decliners, 19 advances and 3 flats;

Mid-day (1 pm): NEUTRAL with 20 decliners, 20 advancers and 3 flats;

Closing bell: POSITIVE with 12 decliner, 28 advancers and 3 flats

Wednesday’s trading indications: 5 hits/ 2 miss

Bluebird bio (BLUE) closed DOWN – speculators are nervous and sold into strength – still a miss;
Intrexon (XON) closed UP – hit;
Capricor (CAPR) closed DOWN – hit;
Cellectis S.A. ADR (CLLS) closed DOWN – hit;
MiMedx (MDXG) closed UP – hit;
Osiris (OSIR) closed UP – hit;
VistaGen (OTCQB: VSTA) closed DOWN – miss;

Riding the indexes and ETFs roller-coaster:

The iShares Biotechnology Stocks ETF (IBB) closed down on Wednesday -1.45 or -0.43% after Tuesday’s advance of +1.02 or +0.30% following Monday’s advance of +12.60 or +3.87%;

The NASDAQ Biotechnology index (NBI) closed down on Wednesday -12.23 or 0.35 % after Tuesday’s advance of +3.74 or +0.11% following Monday’s advance of +131.08 or +3.84%;

The Russell 2000 (IWM) closed down on Wednesday -0.06 or -0.05% after Tuesday’s advance of+0.61 or +0.52% following Monday’s +2.40 or +2.08%;

The SPDR SD&P Biotech ETF (XBI) closed up on Wednesday +0.40 or +0.56% after Tuesday +0.64 or +0.90% following Monday’s advance of +4.48 or +5.72%;

Who closed down – top 5:

Cellectis ADR (CLLS) closed down -$3.57 to $35.01;
Bluebird bio (BLUE) -$3.49 to $90.15;
VistaGen (VSTA) -$0.40 to $6.60;
Stemline (STML) -$0.16 to $8.95;
Histogenics (HSGX) closed down -$0.13 to $4.26

Who was UP – top 5:

Spark Therapeutics ONCE) closed up +$2.77 to $60.03;
uniQure (QURE) +$1.56 to $20.59;
Intrexon (XON) +$0.94 to $40.36;
Regenxbio (RGNX) +$0.90 to $18.03;
Applied Genetic technologies (AGTC) closed up +40.71 to $13.79

Flat:

BioLife Solutions (BLFS) at $2.25;
Mesoblast ADR (USOTC: MBLTY) at $12.33;
ReNeuron (RENE.L) at $3.75;

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.